~~<i id='7A3F4D7822'><strike id='7A3F4D7822'><tt id='7A3F4D7822'><pre id='7A3F4D7822'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

focus

author：explore 2025-09-01 15:17:24 - browse：94

It’s that time of the year again when I recognize the Best Biopharma CEO of the year.

This year’s selection is so deservingly obvious that I won’t fabricate suspense by starting with an honor roll of runners-up. More on those high-achieving folks later. Let’s get right to the main course: David Ricks of Eli Lillyis the runaway, rock star, who-else-could-it-be Best Biopharma CEO of 2023.

What an incredible year it’s been for Ricks and the Lilly executive team who helped him achieve so much. My colleague Matt Herper wrote earlier this year about the “dynamic duo” of Ricks and Chief Scientific Officer Dan Skovronsky.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Cosmetics set for new safety regulation. Why the industry is on board

focus

leisure time

hotspot

entertainment

hotspot

explore

AdobeThebodymassindexhaslongbeenslammedasabluntinstrumentforevaluatinghealth,evenmoresowithnewobesit

WSS

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

NIH documents show early flaws of $1.6 billion long Covid program

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

NIH documents show early flaws of $1.6 billion long Covid program

Google and Epic fight stronger regulation of AI in health care

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Wikipedia

focus

focus

Moonlake's readout produced a cash windfall. Risks remain

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Peter Hotez and the public health issue of online harassment

BMI, flaws aside, is found to be useful estimate of body fat in youth

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Let's speed up science by embracing open access publishing

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Bright Health sells Medicare Advantage business to Molina

Intellia reports positive results for its CRISPR

leisure time

BMI, flaws aside, is found to be useful estimate of body fat in youth

Ultragenyx gene therapy for rare liver ailment succeeds in late

With trial win, GSK could get blood cancer drug back on market

Let's speed up science by embracing open access publishing

With trial win, GSK could get blood cancer drug back on market

Intellia reports positive results for its CRISPR

hotspot

entertainment

hotspot

explore